Table 1.
Comparison of clinical features in patients with PFS information.
| Clinical Features | Training group (n = 239) | Validation group (n = 100) | p value |
|---|---|---|---|
| Age | |||
| Median (Range) | 61 (33-84) | 61 (26-82) | t-test p=0.217 |
| Gender (n%) | |||
| Male | 97 (40.6) | 32 (32.0) | Pearson χ2 Test p=0.143 |
| Female | 142 (59.4) | 68 (68.0) | |
| Smoking History | |||
| Yes | 55 (23.0) | 17 (17.0) | Pearson χ2 Test p=0.265 |
| No | 184 (77.0) | 83 (83.0) | |
| PFS (months) | |||
| Median | 9 | 9 | Log-rank Test p=0.265 |
| ≤9 months | 138 (57.7) | 56 (56.0) | Pearson χ2 Test p=0.810 |
| >9 months | 101 (42.3) | 44 (44.0) | |
| Clinical Staging | |||
| IIIA | 8 (3.3) | 3 (3.0) | Mann-Whitney Test p=0.989 |
| IIIB | 22 (9.2) | 7 (7.0) | |
| IV | 209 (87.5) | 90 (90.0) | |
| EGFR mutation site | |||
| 19del | 121 (50.6%) | 48 (48%) | Pearson χ2 Test p=0.346 |
| 21L858R | 113 (47.3%) | 47 (47%) | |
| Double Site | 5 (2.1%) | 5 (5%) | |